Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes

P. Cannon, Christopher; E. Pratley, Richard; Dagogo‐Jack, Samuel; P. Mancuso, James; Huyck, Susan; Masiukiewicz, Urszula; Charbonnel, B; Frederich, Robert; Gallo, Silvina; Cosentino, Francesco; Shih, Weichung; Gantz, Ira; G. Terra, Steven; Z.I. Cherney, David; K. McGuire, Darren

doi:10.1056/nejmoa2004967

Public

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes

Published in New England Journal of Medicine • Sep 23, 2020

Authors:

Christopher P. Cannon

Richard E. Pratley

Samuel Dagogo‐Jack

Abstract

BACKGROUND: The cardiovascular effects of ertugliflozin, an inhibitor of sodium-glucose cotransporter 2, have not been established. METHODS: In a multicenter, double-blind trial, we randomly assigned patients with type 2 diabetes and atherosclerotic cardiovascular disease to receive 5 mg or 15 mg of...

Subject

Type 2 diabetes

Medicine

Diabetes mellitus

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!